Fulton Breakefield Broenniman LLC Raises Position in Danaher Co. (NYSE:DHR)

Fulton Breakefield Broenniman LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 0.1% during the 4th quarter, HoldingsChannel reports. The fund owned 99,755 shares of the conglomerate’s stock after acquiring an additional 85 shares during the quarter. Danaher comprises approximately 1.6% of Fulton Breakefield Broenniman LLC’s portfolio, making the stock its 19th biggest holding. Fulton Breakefield Broenniman LLC’s holdings in Danaher were worth $22,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher during the 3rd quarter valued at $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $247.77 on Wednesday. The company has a 50 day moving average price of $235.75 and a 200-day moving average price of $253.65. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The stock has a market capitalization of $178.96 billion, a PE ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is presently 20.61%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Raymond James lowered their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Citigroup decreased their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Robert W. Baird decreased their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $285.81.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.